AtriCure, Inc.ATRCNASDAQ

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

17 analysts·Moderate coverage

100%

Rating Distribution

Strong Buy

00%

Buy

17100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 51% higher.

Bear Case

$54.00

+38%

Consensus

$59.00

+51%

Bull Case

$64.00

+64%

Price Range17 analysts

Low

Consensus

High

$54.00

$64.00

Current Target

Current Price

$39.06

Upside to Target

$19.94

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.10(6 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+12.78%

EPS—

FY2028

Rev+13.51%

EPS+206.44%

FY2029

Rev+12.25%

EPS-3.45%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+37.1%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 30, 2025Canaccord Genuity

AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity

Target:$64.00

+80.6%from $35.44

Jul 30, 2025BTIG

AtriCure price target raised to $54 from $52 at BTIG

Target:$54.00

+53.7%from $35.13

Jul 31, 2024Stifel Nicolaus

AtriCure price target lowered to $26 from $30 at Stifel

Target:$26.00

+18.2%from $22.00

Jul 31, 2024Piper Sandler

AtriCure price target lowered to $40 from $65 at Piper Sandler

Target:$40.00

+81.8%from $22.00

Jul 31, 2024BTIG

AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG

Target:$53.00

+140.9%from $22.00

May 2, 2024Needham

AtriCure Inc. (ATRC) PT Lowered to $40 at Needham

Target:$40.00

+61.6%from $24.76

May 2, 2024BTIG

AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG

Target:$58.00

+134.2%from $24.76

Apr 23, 2024Oppenheimer

Oppenheimer Upgrades AtriCure Inc. (ATRC) to Outperform

Target:$32.00

+40.9%from $22.71

Feb 6, 2023Canaccord Genuity

Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $81

Target:$81.00

+71.6%from $47.20

Dec 19, 2022Needham

AtriCure price target raised to $58 from $55 at Needham

Target:$58.00

+40.2%from $41.37

Aug 3, 2022Piper Sandler

AtriCure price target lowered to $55 from $90 at Piper Sandler

Target:$55.00

+10.7%from $49.69

May 4, 2022Needham

Needham Maintains Buy on AtriCure, Lowers Price Target to $67

Target:$67.00

+22.6%from $54.63

May 4, 2022Leerink Partners

SVB Leerink Maintains Outperform on AtriCure, Lowers Price Target to $75

Target:$75.00

+37.3%from $54.63

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance